Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53.1M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
33.3M
-
Shares change
-
-935K
-
Total reported value, excl. options
-
$160M
-
Value change
-
-$6.35M
-
Put/Call ratio
-
0.07
-
Number of buys
-
34
-
Number of sells
-
-31
-
Price
-
$4.80
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q3 2023
89 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q3 2023.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.3M shares
of 53.1M outstanding shares and own 62.64% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), FMR LLC (5.59M shares), Vivo Capital, LLC (4.22M shares), ORBIMED ADVISORS LLC (2.87M shares), BlackRock Inc. (1.84M shares), Redmile Group, LLC (1.28M shares), BRAIDWELL LP (1.25M shares), VANGUARD GROUP INC (1.01M shares), Logos Global Management LP (1M shares), and Cormorant Asset Management, LP (612K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.